In a study involving patients with cblC deficient methylmalonic acidemia and hydrocephalus, characterized by high blood propionylcarnitine, it was observed that 61.8% of patients had epilepsy, and treatment with l‐carnitine resulted in symptom improvement (He et al., 2020). The gene discussed is CBLC; the disease is epilepsy.